Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Glioblastoma 1Ganglioneuroblastoma 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

fludarabine phosphate 1Specimen Handling 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Leukapheresis × 30 days × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡